For women of childbearing potential only: a negative urine or serum pregnancy test done =< 7 days prior to pre-registration is required
Not pregnant and not nursing; for women of childbearing potential only, a negative urine or serum pregnancy test done =< 8 days prior to registration is required
Serum or urine pregnancy test must be negative in premenopausal women within 14 days of randomization, or in women with amenorrhea of less than 12 months at time of randomization.
Women of childbearing potential must have a negative serum or urine pregnancy test at screening
If the participant is of childbearing potential, she must have a documented negative urine pregnancy test at the time of screening and randomization and no plans to become pregnant for the duration of study participation.
Negative serum/urine pregnancy test (for women of childbearing potential)
Negative pregnancy test by urine or serum or waiver of pregnancy testing per local institutional policy within 30 days prior to randomization according to local standards for women of childbearing potential
Women of childbearing potential must have a negative urine pregnancy test at the screening visit
Women of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug.
Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to the start of the study
Women of childbearing potential (WOCBP) must have negative urine pregnancy test within 7 days of day 1 (D1) of treatment
Women of childbearing potential who are not using an effective method of contraception are excluded. Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to administration of SRS
Patients who are pregnant or nursing; women of childbearing potential (WOCBP) will have to undergo a urine pregnancy test as part of screening
Women of childbearing potential must have a negative serum or urine pregnancy test within 10-14 days prior to enrollment
Women of childbearing potential must have a negative serum or urine pregnancy test.
Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test for the patient to be eligible for trial enrolment
Pregnancy, lactation, or breast-feeding; women of childbearing potential must have a negative urine pregnancy test at screening
Women of childbearing potential must have a negative urine or serum pregnancy test at screening within 14 days prior to randomization
Women of childbearing potential must have a negative serum or urine pregnancy test within 1 day prior to administration of the first dose of chemotherapy
If a female of childbearing potential, has a negative serum blood pregnancy test during screening and a negative urine pregnancy test within 3 days prior to receiving the first dose of study drug; if the screening serum test is done within 3 days prior to receiving the first dose of study drug, a urine test is not required; Note: Women of childbearing potential (WoCP) are any women between menarche and menopause who have not been permanently or surgically sterilized and are capable of procreation; permanent sterilization includes hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy but excludes bilateral tubal occlusion; WoCP include non-women who have experienced menopause onset < 12 months prior to enrollment
Negative serum or urine pregnancy test at screening for women of childbearing potential
Urine pregnancy test is negative for women of childbearing potential, within 14 days before study treatment
A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
DONOR: Women of childbearing potential (WOCBP): Urine pregnancy testing performed within 7 days prior to stem cell mobilization
Women of childbearing potential must have a negative urine or blood pregnancy test within 14 days of study enrollment
Negative serum or urine pregnancy test within 2 weeks before registration for women of childbearing potential
All women of childbearing potential must have a negative urine or serum pregnancy test at screening.
Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test for the patient to be eligible for trial enrollment
Negative urine or serum pregnancy test for women of childbearing potential
Has negative serum or urine pregnancy test for subjects of childbearing potential within 10 days before first dose.
Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study entry
Negative urine pregnancy test within 1 week prior to Cycle 1 Day 1 for each woman of childbearing potential
Negative urine pregnancy test within 1 week prior to Cycle 1 Day 1 for each woman of childbearing potential
PHASE I: Negative urine pregnancy test =< 3 days prior to course 1 day 1 (C1D1) (women of childbearing potential only)
Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment
Negative urine or serum pregnancy test done =< 21 days prior to computed tomography (CT) simulation, for women of childbearing potential only
Negative serum or urine pregnancy test for women with reproductive potential
Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of treatment.
Negative urine or blood pregnancy test for women of childbearing potential
Has negative serum or urine pregnancy test for subjects of childbearing potential
Women of childbearing potential who have a positive result on screening urine pregnancy test
Pregnant or lactating - women of childbearing potential should use appropriate precautions to avoid becoming pregnant; females of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study treatment start
A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
Women of reproductive potential must have negative urine pregnancy test
Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to FDG-PET-MRI
A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
Women of childbearing potential must have a negative serum or urine pregnancy test within 2 weeks prior to initiation of therapy
A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
Negative pregnancy test (urine or serum), within 7 day prior to day 1 of FOLFIRI in women of childbearing potential
For women of childbearing potential, negative urine or serum pregnancy test within 6 weeks prior to study entry
Women of childbearing potential who are not using an effective method of contraception are excluded; women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to administration of SRS
Women who are able to conceive and unwilling to practice and effective method of birth control; women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to treatment
Negative serum or urine pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only
6. Women must not be pregnant or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to start of study drug administration.
Women of childbearing potential must have a negative serum or urine pregnancy test within 28 days prior to initiation of treatment AND confirmed prior to initiation of treatment on day 1
Women who are pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to the start of nivolumab.
A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial
Negative urine or serum pregnancy test for women of childbearing potential within 7 days prior to study entry
Negative pregnancy test (either urine or serum) within 14 days prior to randomization for all women of childbearing potential (above)
Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of the administration of the first study treatment; women must not be lactating
For women of childbearing potential, a negative serum or urine pregnancy test
Women of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test)
Women of childbearing potential (WOCBP) with negative serum or urine pregnancy test within 7 days of day 1 (D1) of treatment
Patients with a negative pregnancy test (urine or serum) must be documented within 28 days of starting treatment for women of childbearing potential (WOCBP)
A urine pregnancy test (within 7 days of enrollment date) is required for women with childbearing potential
Postmenopausal or evidence of non-childbearing status for women of childbearing potential as confirmed by a negative urine or serum pregnancy test within 7 days prior to start of IPs
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to receiving study agents
Negative urine or serum pregnancy test done =< 7 days prior to registration/randomization, for women of childbearing potential only\r\n* NOTE: in the rare case that a woman enrolling on study is of childbearing potential, a pregnancy test is required prior to enrollment on study
Negative serum or urine pregnancy test within 2 weeks prior to registration for women of childbearing potential
Women of childbearing potential must have a negative serum or urine pregnancy test at Screening
If patient is of childbearing potential, she must have a negative blood or urine pregnancy test within 14 days of surgical treatment on study
Women of childbearing potential must have a negative serum or urine pregnancy test at screening
Premenopausal patients must have a negative serum or urine pregnancy test, including women who have had a tubal ligation and for women less than 12 months after the onset of menopause
Pregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)
Women of childbearing potential must have a negative serum/urine pregnancy test
Women of childbearing potential must have negative blood or urine pregnancy test at screening
Pregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)
Pregnant or lactating women; women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline; (postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to treatment
Negative urine or serum pregnancy test in women with childbearing potential (defined as not post-menopausal for 12 months or no previous surgical sterilization), within one week prior to initiation of treatment
Women of childbearing age must have a negative serum or urine pregnancy test prior to the initiation of study drug.
Women of childbearing potential must have a negative serum or urine pregnancy test upon study entry
Serum or urine pregnancy test (for women of childbearing potential) negative =< 7 days of starting treatment
Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on Day 1;
Women of childbearing potential (not surgically sterilized or at least 2 years postmenopausal) must have a negative serum or urine pregnancy test performed within 7 days prior to the start of treatment
Women of childbearing potential must have a negative serum or urine pregnancy test performed ? 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment and during the 3 months following completion of study treatment.
Negative urine pregnancy test within 7 days prior to commencement of dosing in premenopausal women; women of non-childbearing potential may be included without urine pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 year
Women of reproductive potential must have negative urine pregnancy test
Pregnant or breast-feeding women; women of childbearing potential must have a negative urine or serum pregnancy test within 14 days of start of treatment
Negative urine pregnancy test for women of childbearing potential
Urine pregnancy test for women of childbearing potential (defined as not post-menopausal for 12 consecutive months or no previous surgical sterilizations); a negative urine pregnancy test is required within 48 hours of initiating study drug
For women of childbearing potential, have a negative pregnancy test (serum or urine) on Day 1 prior to initiating study treatment.
Serum or urine pregnancy test negative within 2 weeks for women of childbearing potential
Women of childbearing potential must have a negative pregnancy test (urine or serum) performed within 7 days prior to the start of study drug.
Patients who are pregnant or nursing; women of childbearing potential (WOCBP) will have to undergo a urine pregnancy test as part of screening
Negative pregnancy test (urine dipstick or serum) for women of childbearing potential within 2 weeks prior to registration
Negative serum or urine pregnancy test must be obtained within 7 days before the first dose of study drug in women of childbearing potential. Negative results must be available before study drug administration
Women of childbearing age must have a negative urine pregnancy test
Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to the start of SL-701 treatment.
Women of childbearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating.
Women of childbearing potential must have a blood or urine pregnancy test performed a maximum of 7 days before start of study treatment, and a negative result must be documented before start of study treatment
Women of childbearing potential must have a negative urine pregnancy test performed within 7 days before start of study treatment
Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to administration of everolimus
Negative serum or urine pregnancy test for women of childbearing potential only
Women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to treatment
Not pregnant and not nursing; for women of childbearing potential only, a negative urine or serum pregnancy test done =< 14 days prior to registration and confirmation they are not nursing is required
In addition, women of childbearing potential must consent to use adequate contraception throughout protocol therapy; females of childbearing potential must have a negative urine pregnancy test =< 7 days prior to registration
Women of childbearing potential must have a negative urine pregnancy test at screening, and
If the patient is of childbearing potential, the patient must have a negative blood or urine pregnancy test within 14 days of surgical treatment on study
Negative pregnancy test (serum or urine) done =< 7 days prior to registration, for women of childbearing potential only (determined per clinician discretion)
Negative (serum or urine) pregnancy test, for women of childbearing potential only
Negative urine or serum pregnancy test performed =< 7 days prior to registration, for women of childbearing potential only
Women of childbearing potential (WCBP) must have a negative urine pregnancy test within 7 days prior to the first study intervention
Women of childbearing potential must have a negative urine or serum pregnancy test
Not pregnant or nursing; note: a negative (serum or urine) pregnancy test must be documented =< 7 days prior to registration/randomization for women of childbearing potential
A woman of childbearing potential must have a negative serum or urine pregnancy test at screening within 14 days prior to randomization
Patients of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to PET/CT imaging per institution’s standard of care.
Women of reproductive potential must have a urine pregnancy test day of injection
Women of childbearing potential must have a negative pregnancy test (urine or blood) pre-operatively as per the standard hospital policy; a woman of childbearing potential is defined as one who is biologically capable of becoming pregnant
Pregnant and/or breastfeeding; women of childbearing potential must have a negative urine or serum pregnancy test no more than 3 days prior to FDOPA injection
ALL PARTICIPANTS: A negative serum or urine pregnancy test for woman of childbearing potential
Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to first PET/MRI
Woman of childbearing potential, a negative serum or urine pregnancy test
Woman of childbearing potential, a negative serum or urine pregnancy test
If of childbearing potential, negative pre-treatment urine or serum pregnancy test
Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment.
Pregnant or breastfeeding (negative serum or urine pregnancy test required for women of childbearing potential), or unable to maintain use of contraception while on study and for 60 days after the last dose of avelumab
Women of childbearing potential will be required to have a urine pregnancy test
Negative urine pregnancy test for women of childbearing potential within 7 days of baseline [D10]phe dosing
Women of reproductive potential should have a negative serum or urine pregnancy test within one week prior to radiation planning CT scan
Negative serum or urine pregnancy test must be obtained within 7 days prior to the first dose of study drug in women of childbearing potential. Negative results must be available prior to study drug administration. Pregnancy tests will be repeated regularly during treatment
Pregnant women. Women of reproductive potential must have a negative serum or urine pregnancy test performed within 7 day
